Skip to search formSkip to main contentSkip to account menu

SLV 308

Known as: SLV-308, SME-308 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pardoprunox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SLV 308: plasma levels of effective doses in MPTP‐treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans
Review
2003
Review
2003
SLV-308. Solvay.
Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist… 
2001
2001
The novel dopamine D2 receptor partial agonist, SLV-308, reverses motor disability in MPTP-lesioned common marmosets (Callithrix jacchus).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)